Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Radiation Dose during Transarterial Radioembolization: A Dosimetric C… conventional treatment plan · PMID 33358328 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source To evaluate the radiation dose differences for intraprocedural computed tomography (CT) imaging between cone-beam CT an… | Journal of vascular and interventional radiology : JVIR 2026-08-16 13:06:53 | Source |
| ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocel… Lenvatinib · PMID 42358063 | Cancer · Maladie de Parkinson · Sclérose en plaques · Cancer | Ralentissement de la progression · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Lenvatinib is a first-line therapy for hepatocellular carcinoma (HCC), but its clinical efficacy is limited by drug res… | Cancer biology & therapy 2026-08-16 13:06:49 | Source |
| Associations of ADH1B and ALDH2 genotypes and alcohol flushing with d… The Effect of Alcohol on Common Tremor Syndromes · PMID 38465575 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Given the high prevalence of fast-metabolizing alcohol dehydrogenase-1B*2 (ADH1B*2 ) and inactive aldehyde dehydrogenas… | Pharmacogenetics and genomics 2026-08-16 13:06:49 | Source |
| Cost-effectiveness analysis of atezolizumab and bevacizumab as first-… Lenvatinib · PMID 42033418 | Cancer · Maladie de Parkinson · Sclérose en plaques · Cancer | À vérifier | Publication | PubMed | Voir la publication source This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for… | Journal of medical economics 2026-08-16 13:06:49 | Source |
| Integrative multi-omics profiling reveals DRG1 promotes hepatocellula… Lenvatinib · PMID 42498092 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Developmentally regulated GTP-binding protein 1 (DRG1), a member of the GTPase family, has been implicated in cancer pr… | Cellular signalling 2026-08-16 13:06:49 | Source |
| Unveiling the causal pathway of Parkinson's disease dysphonia: A voic… Core Stability and Parkinson Disease · PMID 42068719 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Although artificial intelligence (AI) models have demonstrated high accuracy in diagnosing Parkinson's disease (PD) fro… | Computer methods and programs in biomedicine 2026-08-16 13:06:46 | Source |
| Zonisamide cotreatment delays striatal dopamine transporter reduction… IV Levodopa · PMID 30103971 | Maladie de Parkinson | Ralentissement de la progression | Publication | PubMed | Voir la publication source This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkin… | Journal of the neurological sciences 2026-08-16 13:06:43 | Source |
| Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease:… KW-6002 · PMID 20629136 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once dai… | Movement disorders : official journal of the Movement… 2026-08-16 13:06:42 | Source |
| Study of istradefylline in patients with Parkinson's disease on levod… KW-6002 · PMID 18831530 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily v… | Movement disorders : official journal of the Movement… 2026-08-16 13:06:42 | Source |
| Basal ganglia neurophysiological markers of non-motor symptoms in Par… Implantation of stimulation electrodes in the STN · PMID 42334335 | Maladie de Parkinson | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source BackgroundDeep brain stimulation (DBS) for Parkinson's disease (PD) primarily improves motor symptoms but leaves non-mo… | Journal of Parkinson's disease 2026-08-16 13:06:36 | Source |
| Exploring the gut microbiome and metabolomic interactions of antimeta… 5-Fluorouracil · PMID 41758194 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Antimetabolite drugs are cornerstones in treating various cancers and autoimmune diseases; however, their clinical util… | Gut microbes 2026-08-16 13:06:35 | Source |
| Phytochemical basis and mechanistic insight of Swertia macrosperma in… 5-Fluorouracil · PMID 42409345 | Maladie de Parkinson | Neuroprotection · Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source 5-Fluorouracil (5-FU)-induced diarrhea severely impacts chemotherapy outcomes. Swertia macrosperma (C. B. Clarke) C. B.… | Journal of ethnopharmacology 2026-08-16 13:06:35 | Source |
| Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/A… Cisplatin · PMID 42474358 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Lung cancer presents complex etiopathology involving a mix of genetic predispositions and environmental factors. The be… | Cancer biology & therapy 2026-08-16 13:06:32 | Source |
| A Novel IDO1/NE Dual Inhibitor, IMM-H018 Prevents the Primary and Sec… Epacadostat · PMID 42474642 | Maladie de Parkinson | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Sepsis is characterized by the simultaneous presence of hyperinflammation, immunosuppression, and coagulation abnormali… | Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026-08-16 13:06:31 | Source |
| Current applications and development of dual-target inhibitors of Ido… Epacadostat · PMID 42114227 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are rate-limiting enzymes of the kynurenine p… | European journal of medicinal chemistry 2026-08-16 13:06:31 | Source |
| Incidence, treatment variation, and survival of synchronous head and… Cetuximab · PMID 42583039 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Patients with head and neck squamous cell carcinoma (HNSCC) or esophageal carcinoma (EC) face elevated risk for develop… | ESMO gastrointestinal oncology 2026-08-16 13:06:31 | Source |
| Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-… Cetuximab · PMID 42333517 | Cancer · Maladie de Parkinson · Cancer | Remyélinisation indirecte / réparation · Thérapie génique | Publication | PubMed | Voir la publication source Photosensitizer-based antibody conjugates can provide tumor-selective phototoxicity by combining receptor-mediated targ… | Journal of immunotherapy (Hagerstown, Md. : 1997) 2026-08-16 13:06:31 | Source |
| Novel bispecific T-cell engagers overcoming acquired EGFR resistance. Cetuximab · PMID 42152476 | Cancer · Maladie de Parkinson · Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Epidermal growth factor receptor (EGFR) is a validated therapeutic target in several human cancers harboring wild-type… | mAbs 2026-08-16 13:06:31 | Source |
| Novel multiplex immunofluorescence-based tumor inflammation score pro… Pembrolizumab · PMID 42126144 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Retrospective characterization of cell‒cell relationships in the tumor microenvironment provides significantly better p… | Oncoimmunology 2026-08-16 13:06:30 | Source |
| Muribaculum as a microbial contributor of rifaximin-induced mucosal p… Rifaximin · PMID 42286866 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Chemotherapy-induced intestinal mucositis is a frequent and dose-limiting toxicity that compromises cancer treatment ou… | Gut microbes 2026-08-16 13:06:29 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||